- Home
- RANG vs TLSI Comparison
RANG vs TLSI Comparison
Compare RANG & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANG
- TLSI
- Stock Information
- Founded
- RANG 2024
- TLSI 2010
- Country
- RANG United States
- TLSI United States
- Employees
- RANG N/A
- TLSI N/A
- Industry
- RANG
- TLSI Medical Specialities
- Sector
- RANG
- TLSI Health Care
- Exchange
- RANG Nasdaq
- TLSI Nasdaq
- Market Cap
- RANG 165.2M
- TLSI 160.4M
- IPO Year
- RANG 2024
- TLSI N/A
- Fundamental
- Price
- RANG $10.13
- TLSI $5.02
- Analyst Decision
- RANG
- TLSI Strong Buy
- Analyst Count
- RANG 0
- TLSI 6
- Target Price
- RANG N/A
- TLSI $11.75
- AVG Volume (30 Days)
- RANG 15.6K
- TLSI 33.4K
- Earning Date
- RANG 01-01-0001
- TLSI 05-14-2025
- Dividend Yield
- RANG N/A
- TLSI N/A
- EPS Growth
- RANG N/A
- TLSI N/A
- EPS
- RANG N/A
- TLSI N/A
- Revenue
- RANG N/A
- TLSI $29,431,000.00
- Revenue This Year
- RANG N/A
- TLSI $56.00
- Revenue Next Year
- RANG N/A
- TLSI $52.17
- P/E Ratio
- RANG N/A
- TLSI N/A
- Revenue Growth
- RANG N/A
- TLSI 58.99
- 52 Week Low
- RANG $9.91
- TLSI $3.50
- 52 Week High
- RANG $10.64
- TLSI $10.24
- Technical
- Relative Strength Index (RSI)
- RANG N/A
- TLSI 34.87
- Support Level
- RANG N/A
- TLSI $4.66
- Resistance Level
- RANG N/A
- TLSI $5.40
- Average True Range (ATR)
- RANG 0.00
- TLSI 0.37
- MACD
- RANG 0.00
- TLSI -0.06
- Stochastic Oscillator
- RANG 0.00
- TLSI 29.51
About RANG Range Capital Acquisition Corp. Ordinary Shares
Range Capital Acquisition Corp is a blank check company.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.